Coherus Biosciences Inc Banner Image

Coherus Biosciences Inc

  • Ticker CHRS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Coherus Biosciences Inc Logo Image
  • 51-200 Employees
  • Based in Redwood City, California
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that hasMore completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia.
4.8 / 5.0 (168)

Coherus Biosciences Inc reports have an aggregate usefulness score of 4.8 based on 168 reviews.

Coherus Biosciences Inc

Most Recent Annual Report

Coherus Biosciences Inc
MOST RECENT 2022 Annual Report and Form 10K

Coherus Biosciences Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Coherus Biosciences Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!